Therapeutically, our findings suggest that tumors with intact antigen-processing and presentation machinery (e.g., high-grade gliomas) may be more amenable to immune-based interventions, though such strategies should be carefully balanced to account for the potential upregulation of immunosuppressive pathways (e.g., PD-L1 via IFNγ signaling). This evidence concerns the gene IFNG and central nervous system cancer.